

5th February, 2026

BSE Limited

P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') – Completion of tenure of Independent Director

Pursuant to Regulation 30 of the SEBI Listing Regulations, the Company hereby informs that Mr. Subramanian Ramadorai (DIN: 000000002) completes his term of 5 (five) consecutive years as Independent Director of the Company, on February 8, 2026. Mr. Ramadorai has expressed his desire to retire from the Board in the interest of pursuing personal priorities and has therefore not offered himself up for appointment for a second term.

Accordingly, Mr. Ramadorai ceases to be an Independent Director of the Company with effect from 9th February, 2026 and consequently, as Chairman/Member of the various Board Committees on which he served. The Board has re-constituted the Committees in accordance with applicable regulatory requirements.

The Board places on record its heartfelt gratitude for the valuable insights and guidance received from Mr. Ramadorai during his tenure on the Board. There is no material reason for his cessation other than as mentioned above.

Kindly take this on record and oblige.

Thanking you,

Sincerely,

For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India
T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com